Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The National Institutes of Health intends to award a sole source contract to Life Technologies Corporation for reagents and consumables necessary for their instruments. This acquisition is conducted under FAR Part 13 Simplified Acquisition Procedures, emphasizing the need for validated products to ensure consistent patient testing and avoid delays in care.
The purpose of this acquisition is to purchase reagents and consumables that are needed to run Life Technologies instruments at the Department of Laboratory Medicine (DLM) at National Institutes of Health (NIH) Clinical Center (CC). Product Service Code: 6515 Medical Instruments, Equipment, and Supplies NAICS Code: 339112 Surgical and Medical Instrument Manufacturing Place of Performance: Bethesda, MD 20892 USA POTS: 25-000661 Description: This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. The National Institutes of Health (NIH) intends to award a fixed price purchase order to Life Technologies Corporation, located at 3175 Staley Rd, Grand Island, NY 14072, on a firm fixed price sole source award basis to provide reagents and consumables that are needed to run Life Technologies instruments at the Department of Laboratory Medicine (DLM) at National Institutes of Health (NIH) Clinical Center (CC). Life Technologies Scientific is the sole-source manufacturer and supplier of the consumables and kits that are used in the laboratory. There are other types of kits that are on the market, however, they work differently than what have been validated for our patients. These reagents have been fully validated for use in BCR-ABL fusion assay, cKIT mutation assay and JAK2 mutation assay. Switching to another system would entail lengthy validations and would alter current results of our protocols. The department has been very conscientious about cost savings and has thoroughly investigated and validated patient testing using these consumables and reagents. The possibility of inconsistent data could result from switching vendors and equipment. It could also necessitate additional quality control mechanisms. This could cause potential delays in patient care, protocols and incur unwarranted government expenditure and waste. This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government. Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Kristin Nagashima, Contract Specialist via email to Kristin.nagashima@nih.gov by December 17, 2025 at 12pm EST.
Notice of Intent to Sole Source Life Technologies Corp. is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.